Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
6.42
-0.21 (-3.17%)
At close: Oct 23, 2026, 4:00 PM EDT
6.51
+0.09 (1.40%)
After-hours: Oct 23, 2026, 4:10 PM EDT
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,648,095
Market Cap
138.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Innate Pharma | 120 |
| Armata Pharmaceuticals | 61 |
| Acumen Pharmaceuticals | 61 |
| Protara Therapeutics | 46 |
| Compass Therapeutics | 39 |
| Cue Biopharma | 29 |
| TuHURA Biosciences | 22 |
MSLE News
- 3 days ago - Satellos to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data - TheFly
- 16 days ago - Satellos initiated with a Buy at Craig-Hallum - TheFly
- 19 days ago - Satellos granted composition of matter patent for forazapadin - TheFly
- 19 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - Financial Post
- 19 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - GlobeNewsWire
- 24 days ago - Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD - Nasdaq
- 24 days ago - Satellos announces enrollment completed for BASECAMP - TheFly